Regeneron Pharmaceuticals (NASDAQ:REGN) PT Raised to $750.00

Regeneron Pharmaceuticals (NASDAQ:REGNGet Rating) had its price objective increased by Canaccord Genuity Group from $700.00 to $750.00 in a research note issued to investors on Friday morning, Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other equities research analysts also recently weighed in on the stock. SVB Leerink boosted their price objective on shares of Regeneron Pharmaceuticals from $630.00 to $756.00 and gave the company a market perform rating in a research report on Friday, September 9th. BMO Capital Markets upped their target price on Regeneron Pharmaceuticals from $757.00 to $788.00 and gave the company an outperform rating in a report on Thursday, August 4th. Barclays upped their price objective on Regeneron Pharmaceuticals from $735.00 to $815.00 and gave the stock an overweight rating in a research note on Friday, September 9th. Piper Sandler raised their target price on Regeneron Pharmaceuticals from $692.00 to $775.00 and gave the company an overweight rating in a research note on Tuesday, September 13th. Finally, Jefferies Financial Group raised shares of Regeneron Pharmaceuticals from an underperform rating to a hold rating and increased their price objective for the stock from $536.00 to $675.00 in a report on Thursday, September 8th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of Moderate Buy and a consensus price target of $746.33.

Regeneron Pharmaceuticals Stock Up 0.7 %

Shares of Regeneron Pharmaceuticals stock opened at $715.34 on Friday. The business has a 50-day moving average price of $617.77 and a 200 day moving average price of $639.53. Regeneron Pharmaceuticals has a fifty-two week low of $538.01 and a fifty-two week high of $754.67. The firm has a market cap of $77.98 billion, a P/E ratio of 14.18, a P/E/G ratio of 2.46 and a beta of 0.29. The company has a quick ratio of 4.39, a current ratio of 5.12 and a debt-to-equity ratio of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Rating) last issued its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $9.77 earnings per share for the quarter, missing analysts’ consensus estimates of $9.94 by ($0.17). The firm had revenue of $2.86 billion during the quarter, compared to the consensus estimate of $2.80 billion. Regeneron Pharmaceuticals had a net margin of 39.97% and a return on equity of 36.17%. Regeneron Pharmaceuticals’s revenue was down 44.4% compared to the same quarter last year. During the same quarter last year, the firm posted $27.97 earnings per share. On average, sell-side analysts forecast that Regeneron Pharmaceuticals will post 36.16 earnings per share for the current fiscal year.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 10,453 shares of the firm’s stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $621.29, for a total transaction of $6,494,344.37. Following the completion of the sale, the director now directly owns 18,408 shares in the company, valued at $11,436,706.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, Director Arthur F. Ryan sold 10,453 shares of the company’s stock in a transaction on Thursday, August 4th. The stock was sold at an average price of $621.29, for a total transaction of $6,494,344.37. Following the completion of the sale, the director now directly owns 18,408 shares of the company’s stock, valued at $11,436,706.32. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Bonnie L. Bassler sold 609 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, September 9th. The stock was sold at an average price of $741.00, for a total value of $451,269.00. Following the completion of the transaction, the director now directly owns 1,082 shares in the company, valued at approximately $801,762. The disclosure for this sale can be found here. Insiders have sold 56,740 shares of company stock valued at $35,478,694 in the last quarter. Insiders own 8.99% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in REGN. Core Alternative Capital grew its holdings in shares of Regeneron Pharmaceuticals by 800.0% during the first quarter. Core Alternative Capital now owns 36 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 32 shares in the last quarter. Addison Advisors LLC grew its stake in Regeneron Pharmaceuticals by 220.0% during the 1st quarter. Addison Advisors LLC now owns 48 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 33 shares in the last quarter. ACG Wealth acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $30,000. Delos Wealth Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth approximately $33,000. Finally, Byrne Asset Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $34,000. Institutional investors and hedge funds own 84.92% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

(Get Rating)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

See Also

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.